Key Points
- CVS EVP Tilak Mandadi sold 69,551 shares on May 8 at an average price of $89.58, totaling about $6.23 million. After the sale, he still held 10,133 shares, and the transaction reduced his position by 87.28%.
- CVS posted strong quarterly results, reporting $2.57 EPS versus the $2.21 estimate and revenue of $100.43 billion, topping expectations. Revenue rose 6.2% year over year, and the company guided FY 2026 EPS to $7.30-$7.50.
- Analysts remain broadly bullish on CVS after the earnings beat, with TD Cowen raising its price target to $110 and several other firms also increasing targets. Overall, the stock carries a consensus “Moderate Buy” rating with an average target price of $96.12.
CVS Health Corporation (NYSE:CVS - Get Free Report) EVP Tilak Mandadi sold 69,551 shares of the business's stock in a transaction on Friday, May 8th. The shares were sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the sale, the executive vice president directly owned 10,133 shares in the company, valued at $907,714.14. The trade was a 87.28% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
CVS Health Stock Up 1.8%
CVS opened at $92.22 on Tuesday. The company has a fifty day moving average price of $77.43 and a 200-day moving average price of $78.15. The firm has a market capitalization of $117.67 billion, a P/E ratio of 40.63, a price-to-earnings-growth ratio of 0.88 and a beta of 0.60. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.87 and a quick ratio of 0.66. CVS Health Corporation has a one year low of $58.35 and a one year high of $92.77.
CVS Health (NYSE:CVS - Get Free Report) last released its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, beating analysts' consensus estimates of $2.21 by $0.36. The firm had revenue of $100.43 billion during the quarter, compared to analyst estimates of $94.99 billion. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The business's revenue for the quarter was up 6.2% on a year-over-year basis. During the same period in the previous year, the business earned $2.25 EPS. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Equities research analysts expect that CVS Health Corporation will post 7.48 earnings per share for the current fiscal year.
CVS Health Announces Dividend
The company also recently declared a quarterly dividend, which was paid on Monday, May 4th. Stockholders of record on Thursday, April 23rd were given a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date was Thursday, April 23rd. CVS Health's payout ratio is 117.18%.
CVS Health News Roundup
Here are the key news stories impacting CVS Health this week:
- Positive Sentiment: TD Cowen raised its price target on CVS Health to $110 from $105 and reiterated a buy rating, signaling confidence in further upside after the company’s earnings beat and improved outlook. TD Cowen adjusts price target on CVS Health to 110 from 105
- Positive Sentiment: Recent coverage highlights CVS as a potentially undervalued stock, pointing to strong Q1 revenue growth, higher EPS, and improving margins/medical benefit ratio as signs that fundamentals are strengthening. CVS Health: Still Cheap And Signs Of Improvement
- Positive Sentiment: Commentary from CNBC’s “Final Trades” and other market chatter suggests CVS remains a favored healthcare name among some investors, adding to the bullish tone. Nvidia, CVS Health, Vertiv and an energy stock on CNBC's Final Trades
- Neutral Sentiment: An executive stock sale by EVP Tilak Mandadi was disclosed, with 69,551 shares sold at an average price of $89.58. While insider selling can draw attention, the transaction appears more likely to be viewed as portfolio-related than a fundamental red flag. SEC Form 4 filing
- Neutral Sentiment: Additional articles this weekend argued CVS looks like a strong value stock and could benefit from broader healthcare policy trends, reinforcing the current bullish narrative but without new company-specific catalysts. Here's Why CVS Health (CVS) is a Strong Value Stock
Analyst Upgrades and Downgrades
A number of research analysts have recently commented on the stock. Royal Bank Of Canada boosted their price target on shares of CVS Health from $93.00 to $107.00 and gave the company an "outperform" rating in a research report on Thursday. The Goldman Sachs Group boosted their price target on shares of CVS Health from $95.00 to $97.00 and gave the company a "buy" rating in a research report on Thursday, February 12th. DA Davidson boosted their price target on shares of CVS Health from $80.00 to $100.00 and gave the company a "buy" rating in a research report on Thursday, May 7th. Leerink Partners reiterated an "outperform" rating and issued a $98.00 target price on shares of CVS Health in a research report on Thursday, March 5th. Finally, Piper Sandler reduced their target price on CVS Health from $101.00 to $99.00 and set an "overweight" rating on the stock in a research note on Tuesday, March 31st. Twenty-two equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $96.12.
View Our Latest Analysis on CVS Health
Institutional Investors Weigh In On CVS Health
A number of large investors have recently added to or reduced their stakes in CVS. Sei Investments Co. raised its position in CVS Health by 17.4% during the second quarter. Sei Investments Co. now owns 905,715 shares of the pharmacy operator's stock valued at $62,474,000 after purchasing an additional 134,535 shares in the last quarter. The Manufacturers Life Insurance Company raised its position in CVS Health by 1.2% during the second quarter. The Manufacturers Life Insurance Company now owns 1,121,377 shares of the pharmacy operator's stock valued at $77,353,000 after purchasing an additional 13,329 shares in the last quarter. Treasurer of the State of North Carolina raised its position in CVS Health by 1.3% during the second quarter. Treasurer of the State of North Carolina now owns 585,073 shares of the pharmacy operator's stock valued at $40,358,000 after purchasing an additional 7,588 shares in the last quarter. HUB Investment Partners LLC lifted its stake in CVS Health by 25.0% in the second quarter. HUB Investment Partners LLC now owns 15,063 shares of the pharmacy operator's stock worth $1,039,000 after purchasing an additional 3,011 shares during the last quarter. Finally, Alliancebernstein L.P. lifted its stake in CVS Health by 8.0% in the second quarter. Alliancebernstein L.P. now owns 1,609,404 shares of the pharmacy operator's stock worth $111,017,000 after purchasing an additional 119,439 shares during the last quarter. Hedge funds and other institutional investors own 80.66% of the company's stock.
About CVS Health
(
Get Free Report)
CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.
Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
